Stockreport

Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point [Seeking Alpha]

Centessa Pharmaceuticals plc - American Depositary Shares  (CNTA) 
PDF PRESent-3 is another registrational study using SerpinPC for the treatment of patients with Hemophilia B, however it is for the targeting of such patients with inhibito [Read more]